Indications
Ranexa is indicated for the treatment
of chronic angina.
Ranexa may be used with betablockers, nitrates, calcium channel
blockers, anti-platelet therapy, lipidlowering therapy, ACE inhibitors, and
angiotensin receptor blockers.
Important Safety Information
Contraindications
Ranexa is contraindicated in patients:
- Taking strong inhibitors of CYP3A
(e.g., ketoconazole, itraconazole,
clarithromycin, nefazodone,
nelfinavir, ritonavir, indinavir,
and saquinavir).
- Taking inducers of CYP3A (e.g.,
rifampin, rifabutin, rifapentine,
phenobarbital, phenytoin,
carbamazepine, and St John’s wort)
- With liver cirrhosis
Warnings and Precautions
Ranexa blocks lKr and prolongs the
QTc interval in a dose-related manner.
Clinical experience in an acute
coronary syndrome population
did not show an increased risk of
proarrhythmia or sudden death.
However, there is little experience with
high doses (> 1000 mg twice daily) or
exposure, with other QT-prolonging
drugs, with potassium channel
variants resulting in a long QT interval,
in patients with a family history of (or
congenital) long QT syndrome, or
in patients with known acquired QT
interval prolongation.
Acute renal failure has been
observed in patients with severe
renal impairment while on Ranexa.
Monitor renal function after initiation
and periodically in patients with
moderate to severe renal impairment.
Discontinue Ranexa if acute renal
failure develops.
Adverse Reac tions
The most common adverse reactions
(> 4% and more common than
with placebo) during treatment with
Ranexa were dizziness, headache,
constipation, and nausea.
Dosage and Administration
Begin treatment with 500 mg twice